CTT2274

CTT2274 is a prodrug of MMAE. It consists of a prostate-specific membrane antigen (PSMA) binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and an MMAE payload. CTT2274 selectively targets and binds to PSMA to deliver MMAE and has the capability to inhibit prostate cancer.

CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)OC(=O)N(C)CCN(C)P(=O)(O)OCC[C@@H](C(=O)O)NC(=O)C4=CC=C(C=C4)CN5C6=C(C7=CC=CC=C7N(CC8=CC=CC=C86)C(=O)CCC(=O)N[C@@H](CC9=CC=C(C=C9)C1=CC=CC=C1)C(=O)NCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCCOP(=O)(N[C@@H](CCC(=O)O)C(=O)O)O)C(=O)O)C(=O)O)N=N5